Abstract
Pancreatic ductal adenocarcinoma (PDAC) is the leading cause of cancer-related death worldwide. As PDAC is more common in older adults and the population is aging, the incidence of pancreatic adenocarcinoma is expected to increase in the coming years. As a result, the mechanism and clinical management of PDAC in the elderly population is receiving more attention. This review will discuss age-related morphological and pathological changes, clinical management, surgery and adjuvant therapies, and molecular changes in elderly PDAC patients. More research is needed to clarify molecular mechanisms and develop new prevention and treatment strategies for PDAC in elderly patients.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
